Oragenics, Inc. — Form 10-Q Summary
Business context and reporting period
Quarterly report for the period ended September 30, 2016, filed November 14, 2016. Oragenics is a development-stage biotechnology company focused on lantibiotic antibiotics and an oral mucositis treatment. It sold its consumer probiotics business in June 2016; the reported periods therefore include results from that business as discontinued operations. Continuing-operations revenue was zero.
Key financial metrics
| Metric | Three months ended September 30, 2016 | Nine months ended September 30, 2016 |
|---|---|---|
| Continuing-operations revenue | $0 | $0 |
| Research and development expense | $924,800 | $2,978,775 |
| General and administrative expense | $1,101,870 | $2,855,822 |
| Net loss from continuing operations | $2,005,573 | $5,813,133 |
| Profit from discontinued operations | $42,566 | $20,882 |
| Gain on sale of discontinued business | — | $1,453,744 |
| Net loss | $1,963,007 | $4,338,507 |
| Basic and diluted net loss per share | $0.04 | $0.10 |
For the nine months, operating cash use was $5.11 million; investing activities provided $1.68 million, primarily from the business sale and collection of a note receivable; financing activities provided $3.51 million, largely from the private placement and stock subscription collections. Cash and cash equivalents were $5.12 million at September 30, versus $5.08 million at December 31, 2015. Working capital was $4.38 million. Current liabilities were $909,280, including $111,707 of short-term notes payable; the filing reports no material long-term debt. Shareholders’ equity was $4.49 million and accumulated deficit was $91.99 million. Gross margins are not meaningful for continuing operations, which had no revenue.
Changes versus prior comparable periods
- Nine-month R&D expense fell $4.41 million year over year, primarily because the 2015 period included a $5.0 million technology access fee paid through a convertible note to Intrexon. R&D costs under the collaborations increased in 2016.
- Nine-month G&A expense increased $663,348, or 30.3%, to $2.86 million, reflecting higher salaries, professional and filing costs, and stock compensation.
- Nine-month net loss improved from $9.49 million to $4.34 million; this includes a $1.45 million gain on the sale of the probiotics business. Net loss from continuing operations improved from $9.62 million to $5.81 million.
- Quarterly net loss increased from $1.86 million to $1.96 million, as higher G&A more than offset lower R&D expense.
- Operating cash use rose from $3.53 million to $5.11 million year over year. The business sale and equity financing helped keep cash roughly level during the nine-month period.
Outlook, risks, and notable items
- Management expects substantial future losses and says additional financing is required. The filing gives differing runway estimates: one passage says working capital plus the anticipated stock subscription payment should fund current objectives through February 2017; other passages say through April 2017. These estimates are conditional and not a guarantee.
- At September 30, $1,015,334 remained due on the stock subscription receivable. The related-party Koski Family Limited Partnership note was amended: $1 million was paid September 30, the remaining balance was extended to December 31, 2016, and the interest rate rose from 3% to 6%.
- The June private placement issued 9,045,679 shares at $0.5159 per share and raised approximately $4.667 million, including the amount due under the KFLP note. Additional equity or debt financing may dilute shareholders or impose senior rights; no committed financing source was disclosed.
- The company selected OG716, a second-generation lantibiotic candidate for C. difficile, in August 2016 and expected to pursue an IND filing in 2017, subject to available capital. Following FDA feedback, it expected to file an AG013 IND amendment in early 2017 and then begin a Phase 2 study, also subject to financing. These are forward-looking plans, not assured milestones.
- None of the disclosed Intrexon collaboration milestones had been achieved as of September 30. Potential contractual payments are significant, including AG013 milestones of $2 million to $10 million for specified development and approval events, plus other $5 million milestones.
- The 2015 audit report included an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern. The company also remained subject to NYSE MKT compliance monitoring, with a plan deadline of November 10, 2017; failure to comply or make progress could lead to delisting proceedings.
- The probiotics business was sold to ProBiora Health, an entity owned by a then-director, for $1.7 million plus contingent consideration based on sales, capped at $2 million. The transaction received approval from a special committee of disinterested directors and a fairness opinion. The company retained temporary transition and fulfillment arrangements.
- In November 2016, after quarter-end, the board approved a proposal to increase authorized common shares from 100 million to 250 million, subject to shareholder approval. The company said the increase would provide financing flexibility.
- Management reported effective disclosure controls as of September 30 and no significant changes in internal control over financial reporting during the quarter. No material pending legal proceedings were reported.
Important facts for investors to verify
- Actual collection and timing of the remaining $1,015,334 stock subscription receivable and the KFLP note balance due by December 31, 2016.
- Updated cash runway and financing plans, particularly given the filing’s inconsistent February and April 2017 runway estimates and continuing operating cash outflows.
- Progress on OG716 and AG013 development, regulatory interactions, trial timing, and the capital required to reach each milestone.
- NYSE MKT compliance progress and shareholder approval status for the proposed increase in authorized shares.
- Potential dilution and related-party interests, including the ownership stakes of KFLP and Intrexon and the terms and future proceeds of the probiotics business sale.